2.31
+0.05(+2.21%)
Currency In USD
| Previous Close | 2.26 |
| Open | 2.29 |
| Day High | 2.39 |
| Day Low | 2.23 |
| 52-Week High | 8.72 |
| 52-Week Low | 1.15 |
| Volume | 3.71M |
| Average Volume | 4.28M |
| Market Cap | 358.32M |
| PE | -3.4 |
| EPS | -0.68 |
| Moving Average 50 Days | 2.42 |
| Moving Average 200 Days | 3.32 |
| Change | 0.05 |
If you invested $1000 in Humacyte, Inc. (HUMA) since IPO date, it would be worth $235.78 as of August 05, 2025 at a share price of $2.28. Whereas If you bought $1000 worth of Humacyte, Inc. (HUMA) shares 3 years ago, it would be worth $651.43 as of August 05, 2025 at a share price of $2.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Humacyte Announces First Symvess™ Sale to Military Treatment Facility
GlobeNewswire Inc.
Jul 23, 2025 12:00 PM GMT
Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities DURHAM, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- H
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
GlobeNewswire Inc.
Jul 08, 2025 12:00 PM GMT
Electronic Catalog listing approval makes Symvess available to healthcare professionals at U.S. Department of Defense and U.S. Department of Veterans Affairs facilitiesDURHAM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a
Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
GlobeNewswire Inc.
Jun 09, 2025 12:00 PM GMT
Benefits of Humacyte’s Acellular Tissue Engineered Vessel Over Autologous Arteriovenous Fistula (AVF) in High-Risk Patients with End-Stage Kidney Disease Observed in Data Presented in Plenary SessionDURHAM, N.C., June 09, 2025 (GLOBE NEWSWIRE) -- H